Companies Dominating the Advanced Renal Cell Carcinoma Treatment Landscape
- Ono Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Bristol Myers Squibb Company
- Bayer AG
- Pfizer Inc.
- AbbVie Inc.
- Teva Pharmaceuticals Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of advanced renal cell carcinoma treatment is evaluated at USD 7.35 billion.
The advanced renal cell carcinoma treatment market size was over USD 6.71 billion in 2024 and is poised to exceed USD 13.96 billion by 2037, witnessing over 5.8% CAGR during the forecast period i.e., between 2025-2037. Growing proportion of geriatric population, worldwide increasing ratio of smoking, and an upsurge in hypertension will boost the market growth.
North America industry is predicted to account for largest revenue share by 2037, attributed to increasing prevalence of renal cell carcinoma and other cancers in the region.
The major players in the market are Ono Pharmaceutical Co., Ltd., Novartis AG, Merck & Co., Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Bayer AG, Pfizer Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd.
